Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony T Reder

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
Plos One|December 22, 2018
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatmentFredrika Koskimäki, Jacqueline Bernard, Jeong Yong, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 19, 2022
Increased Percentage of CD8<sup>+</sup>CD28<sup>-</sup> Regulatory T Cells With Fingolimod Therapy in Multiple SclerosisTimothy W Houston, Quentin Howlett-Prieto, Colin Regenauer, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|May 15, 2012
Homonymous hemimacular thinning: a unique presentation of optic tract injury in neuromyelitis opticaRebecca S Romero, Ismael Gutierrez, Eugene Wang, et al.
Plos One|December 6, 2011
Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MSDouglas S Goodin, Jason Jones, David Li, et al.
Current Medical Research and Opinion|August 15, 2009
Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining commandMark S Freedman, Bruce Cohen, Suhayl Dhib-Jalbut, et al.
CNS Drugs|July 6, 2021
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)Stanley L Cohan, Barry A Hendin, Anthony T Reder, et al.
Physiological Reports|December 8, 2025
Impaired inactive limb blood flow regulation in adults with multiple sclerosis during sympathoexcitatory stimuliSara R Sherman, Natalia S Lima, Robert W Motl, et al.
Ophthalmology|March 28, 2013
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosisMarco A Zarbin, Lee M Jampol, Rama D Jager, et al.
Journal of the Neurological Sciences|November 1, 2011
Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosisXuan Feng, Nicholas P Reder, Mounica Yanamandala, et al.
Frontiers in Immunology|May 22, 2023
Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patientsKiel M Telesford, Lilyana Amezcua, Lauren Tardo, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
Plos One|December 22, 2018
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatmentFredrika Koskimäki, Jacqueline Bernard, Jeong Yong, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|December 19, 2022
Increased Percentage of CD8<sup>+</sup>CD28<sup>-</sup> Regulatory T Cells With Fingolimod Therapy in Multiple SclerosisTimothy W Houston, Quentin Howlett-Prieto, Colin Regenauer, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|May 15, 2012
Homonymous hemimacular thinning: a unique presentation of optic tract injury in neuromyelitis opticaRebecca S Romero, Ismael Gutierrez, Eugene Wang, et al.
Plos One|December 6, 2011
Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MSDouglas S Goodin, Jason Jones, David Li, et al.
Current Medical Research and Opinion|August 15, 2009
Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining commandMark S Freedman, Bruce Cohen, Suhayl Dhib-Jalbut, et al.
CNS Drugs|July 6, 2021
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)Stanley L Cohan, Barry A Hendin, Anthony T Reder, et al.
Physiological Reports|December 8, 2025
Impaired inactive limb blood flow regulation in adults with multiple sclerosis during sympathoexcitatory stimuliSara R Sherman, Natalia S Lima, Robert W Motl, et al.
Ophthalmology|March 28, 2013
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosisMarco A Zarbin, Lee M Jampol, Rama D Jager, et al.
Journal of the Neurological Sciences|November 1, 2011
Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosisXuan Feng, Nicholas P Reder, Mounica Yanamandala, et al.
Frontiers in Immunology|May 22, 2023
Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patientsKiel M Telesford, Lilyana Amezcua, Lauren Tardo, et al.
Pageof 9